## FROM THE EDITOR

Dear Colleague,

The *Journal of Opioid Management* is pleased to present this special issue titled *Abuse Deterrent Opioids: Clinical and Public Policy Implications.* The journal thanks the authors, and especially our special issue editor, Dr. Lynn Webster, MD, FACPM, FASAM for their many months of work on behalf of this special issue. Dr. Webster, the authors, and reviewers, worked tirelessly to produce quality work regarding the latest formulations of opioid therapy.

The increased use, along with increased misuse and abuse, of opioids over the last two decades is now considered to be a public health crisis. Concerned physicians, the general public, and the Center for Disease Control have all looked for solutions to this complicated health issue. Newer formulations of opioids that are packaged with some form of abuse deterrence, are hoped to help minimize current opioid abuse. The issue of opioid addiction and diversion is complex and will not be solved with a single class of analgesics, however ADF opioids may contribute a piece of the solution puzzle. It is hoped that future ADF opioids will reduce downstream diversion and give health care providers one more tool to help prevent opioid misuse while creating a personalized patient-centered treatment program.

I look forward to future opioid abuse deterrent formulations, which may be available at a reduced cost, to help us combat prescription opioid misuse. Thank you colleague for your dedication to this field and for your commitment to lifelong medical learning.

Sincerely,

Paul A. Sloan

Paul A. Sloan, MD Editor-in Chief, Journal of Opioid Management